Literature DB >> 26646247

Targeted silver nanoparticles for ratiometric cell phenotyping.

Anne-Mari A Willmore1, Lorena Simón-Gracia1, Kadri Toome1, Päärn Paiste2, Venkata Ramana Kotamraju3, Tarmo Mölder1, Kazuki N Sugahara3, Erkki Ruoslahti4, Gary B Braun3, Tambet Teesalu5.   

Abstract

Affinity targeting is used to deliver nanoparticles to cells and tissues. For efficient targeting, it is critical to consider the expression and accessibility of the relevant receptors in the target cells. Here, we describe isotopically barcoded silver nanoparticles (AgNPs) as a tool for auditing affinity ligand receptors in cells. Tumor penetrating peptide RPARPAR (receptor: NRP-1) and tumor homing peptide GKRK (receptor: p32) were used as affinity ligands on the AgNPs. The binding and uptake of the peptide-functionalized AgNPs by cultured PPC-1 prostate cancer and M21 melanoma cells was dependent on the cell surface expression of the cognate peptide receptors. Barcoded peptide-functionalized AgNPs were synthesized from silver and palladium isotopes. The cells were incubated with a cocktail of the barcoded nanoparticles [RPARPAR (R), GKRK (K), and control], and cellular binding and internalization of each type of nanoparticle was assessed by inductively coupled plasma mass spectrometry. The results of isotopic analysis were in agreement with data obtained using optical methods. Using ratiometric measurements, we were able to classify the PPC-1 cell line as mainly NRP-1-positive, with 75 ± 5% R-AgNP uptake, and the M21 cell line as only p32-positive, with 89 ± 9% K-AgNP uptake. The isotopically barcoded multiplexed AgNPs are useful as an in vitro ratiometric phenotyping tool and have potential uses in functional evaluation of the expression of accessible homing peptide receptors in vivo.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26646247      PMCID: PMC4850089          DOI: 10.1039/c5nr07928d

Source DB:  PubMed          Journal:  Nanoscale        ISSN: 2040-3364            Impact factor:   7.790


  17 in total

1.  Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer.

Authors:  William J Gradishar; Sergei Tjulandin; Neville Davidson; Heather Shaw; Neil Desai; Paul Bhar; Michael Hawkins; Joyce O'Shaughnessy
Journal:  J Clin Oncol       Date:  2005-09-19       Impact factor: 44.544

2.  Proapoptotic peptide-mediated cancer therapy targeted to cell surface p32.

Authors:  Lilach Agemy; Venkata R Kotamraju; Dinorah Friedmann-Morvinski; Shweta Sharma; Kazuki N Sugahara; Erkki Ruoslahti
Journal:  Mol Ther       Date:  2013-08-20       Impact factor: 11.454

3.  Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs.

Authors:  Kazuki N Sugahara; Tambet Teesalu; Priya Prakash Karmali; Venkata Ramana Kotamraju; Lilach Agemy; Daniel R Greenwald; Erkki Ruoslahti
Journal:  Science       Date:  2010-04-08       Impact factor: 47.728

4.  Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer.

Authors:  M R Green; G M Manikhas; S Orlov; B Afanasyev; A M Makhson; P Bhar; M J Hawkins
Journal:  Ann Oncol       Date:  2006-06-01       Impact factor: 32.976

5.  VEGF overexpression in clinically localized prostate tumors and neuropilin-1 overexpression in metastatic forms.

Authors:  A Latil; I Bièche; S Pesche; A Valéri; G Fournier; O Cussenot; R Lidereau
Journal:  Int J Cancer       Date:  2000-03-20       Impact factor: 7.396

6.  Progressive vascular changes in a transgenic mouse model of squamous cell carcinoma.

Authors:  Jason A Hoffman; Enrico Giraudo; Mallika Singh; Lianglin Zhang; Masahiro Inoue; Kimmo Porkka; Douglas Hanahan; Erkki Ruoslahti
Journal:  Cancer Cell       Date:  2003-11       Impact factor: 31.743

7.  Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes.

Authors:  A Gabizon; R Catane; B Uziely; B Kaufman; T Safra; R Cohen; F Martin; A Huang; Y Barenholz
Journal:  Cancer Res       Date:  1994-02-15       Impact factor: 12.701

8.  Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer.

Authors:  M E R O'Brien; N Wigler; M Inbar; R Rosso; E Grischke; A Santoro; R Catane; D G Kieback; P Tomczak; S P Ackland; F Orlandi; L Mellars; L Alland; C Tendler
Journal:  Ann Oncol       Date:  2004-03       Impact factor: 32.976

9.  C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration.

Authors:  Tambet Teesalu; Kazuki N Sugahara; Venkata Ramana Kotamraju; Erkki Ruoslahti
Journal:  Proc Natl Acad Sci U S A       Date:  2009-09-02       Impact factor: 11.205

10.  Etchable plasmonic nanoparticle probes to image and quantify cellular internalization.

Authors:  Gary B Braun; Tomas Friman; Hong-Bo Pang; Alessia Pallaoro; Tatiana Hurtado de Mendoza; Anne-Mari A Willmore; Venkata Ramana Kotamraju; Aman P Mann; Zhi-Gang She; Kazuki N Sugahara; Norbert O Reich; Tambet Teesalu; Erkki Ruoslahti
Journal:  Nat Mater       Date:  2014-06-08       Impact factor: 43.841

View more
  10 in total

1.  iRGD peptide conjugation potentiates intraperitoneal tumor delivery of paclitaxel with polymersomes.

Authors:  Lorena Simón-Gracia; Hedi Hunt; Pablo Scodeller; Jens Gaitzsch; Venkata Ramana Kotamraju; Kazuki N Sugahara; Olav Tammik; Erkki Ruoslahti; Giuseppe Battaglia; Tambet Teesalu
Journal:  Biomaterials       Date:  2016-07-20       Impact factor: 12.479

2.  Cell-Penetrating Peptides.

Authors:  Matjaž Zorko; Ülo Langel
Journal:  Methods Mol Biol       Date:  2022

3.  Isolation of Primary Hepatocytes for Testing Tumor Penetrating Peptides.

Authors:  Eric Savier; Pierre Tuffery; Heriberto Bruzzoni-Giovanelli; Angelita Rebollo
Journal:  Methods Mol Biol       Date:  2022

4.  Competition of charge-mediated and specific binding by peptide-tagged cationic liposome-DNA nanoparticles in vitro and in vivo.

Authors:  Emily Wonder; Lorena Simón-Gracia; Pablo Scodeller; Ramsey N Majzoub; Venkata Ramana Kotamraju; Kai K Ewert; Tambet Teesalu; Cyrus R Safinya
Journal:  Biomaterials       Date:  2018-03-02       Impact factor: 12.479

5.  Ratiometric in vivo auditioning of targeted silver nanoparticles.

Authors:  Kadri Toome; Anne-Mari A Willmore; Päärn Paiste; Allan Tobi; Kazuki N Sugahara; Kalle Kirsimäe; Erkki Ruoslahti; Gary B Braun; Tambet Teesalu
Journal:  Nanoscale       Date:  2017-07-20       Impact factor: 7.790

Review 6.  Photodynamic Therapy for Metastatic Melanoma Treatment: A Review.

Authors:  Channay Naidoo; Cherie Ann Kruger; Heidi Abrahamse
Journal:  Technol Cancer Res Treat       Date:  2018-01-01

7.  Novel Anthracycline Utorubicin for Cancer Therapy.

Authors:  Lorena Simón-Gracia; Valeria Sidorenko; Ain Uustare; Ivan Ogibalov; Andrus Tasa; Olga Tshubrik; Tambet Teesalu
Journal:  Angew Chem Int Ed Engl       Date:  2021-06-01       Impact factor: 16.823

Review 8.  Peritoneal Carcinomatosis Targeting with Tumor Homing Peptides.

Authors:  Lorena Simón-Gracia; Hedi Hunt; Tambet Teesalu
Journal:  Molecules       Date:  2018-05-16       Impact factor: 4.411

Review 9.  Nanoparticles Modified with Cell-Penetrating Peptides: Conjugation Mechanisms, Physicochemical Properties, and Application in Cancer Diagnosis and Therapy.

Authors:  Isabel Gessner; Ines Neundorf
Journal:  Int J Mol Sci       Date:  2020-04-06       Impact factor: 5.923

Review 10.  The Peptide Functionalized Inorganic Nanoparticles for Cancer-Related Bioanalytical and Biomedical Applications.

Authors:  Xiaotong Li; Minghong Jian; Yanhong Sun; Qunyan Zhu; Zhenxin Wang
Journal:  Molecules       Date:  2021-05-27       Impact factor: 4.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.